mRNA-4157
Phase 2RNA therapy
ModernamRNA-4157 is one of 53 small molecule programs targeting Melanoma. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Paraplatin
AAvyxa
Phase 3
ABP 234
AmgenPhase 3
GSK 257049
GSKPhase 3
GSK2118436
GSKPhase 3
Anti-PD1
PfizerPhase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Preclinical
Intron a
Merck & Co.Preclinical
Opdualag
Bristol-Myers SquibbPreclinical
PEG-Intron
Merck & Co.Preclinical
Talimogene Laherparepvec
AmgenPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Immunogenicity1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for mRNA-4157. EMBL-EBI & Wellcome Sanger Institute.
- [4]